Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 15

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 15
---
 be exposed to liabilities under the U.S. Foreign Corrupt Practices Act and similar anti-corruption and                                                                                                                                      
 anti-bribery laws of the PRC and other countries in which we operate, as well as U.S. and foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in 
 foreign markets and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.                                                                                                     |

| • |     | We are subject to various foreign, federal, and state healthcare laws and regulations, and failure to comply 
 with these laws and regulations could harm our results of operations and financial condition.                |

| • |     | Actual or perceived failures to comply with applicable data protection, privacy and security laws,                                 
 regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition. |

| • |     | Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty                     
 and cost for us to obtain marketing approval for and commercialize our Product Candidates and may affect the prices we may set. |

| • |     | Some of our investments may be subject to review from the Committee on Foreign Investment in the U.S. which 
 may delay or block a transaction from closing.                                                              |

| • |     | If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required 
 to limit commercialization of our products.                                                                    |

| • |     | Our IT Systems, or those of our CROs, manufacturers, other contractors, vendors, consultants or collaborators,                                                                                                                                           
 may fail or suffer system failures, security breaches or deficiencies in cybersecurity, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or trigger contractual 
 and legal obligations.                                                                                                                                                                                                                                   |

| • |     | Our employees and independent contractors, including principal investigators, CROs, consultants and vendors,               
 may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. |

| • |     | We may engage in strategic transactions that could impact our liquidity, increase our expenses and present 
 significant distractions to our management.                                                                |

| • |     | Significant changes or developments in U.S. laws or policies, including changes in U.S. trade policies and                                                  
 tariffs and the reaction of other countries thereto, may have a material and adverse effect on our business, financial condition and results of operations. |

R